Poulvac IB H120 Vaccine

국가: 영국

언어: 영어

출처: VMD (Veterinary Medicines Directorate)

유효 성분:

Infectious bronchitis virus

제공처:

Zoetis UK Limited

ATC 코드:

QI01AD07

INN (국제 이름):

Infectious bronchitis virus

승인 상태:

Expired

제품 특성 요약

Issued: July 2013
AN. 01269/2012
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Poulvac IB H120 Vaccine
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES PER DOSE:
Live, attenuated Avian Infectious Bronchitis Virus Strain H120: 10
3.0
– 10
4.9
EID
50
EXCIPIENTS:
For a full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Oral solution, eye drops solution or spray solution after
reconstitution of the freeze-
dried vaccine in water.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens from the age of one day
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the vaccination of chickens to prevent respiratory disease caused
by
Massachusetts strains of avian infectious bronchitis virus and to act
as a live primer for
inactivated Massachusetts strain vaccines.
Onset of immunity: 25 days post vaccination
Duration of immunity: Protection of chicks will be of approximately 16
weeks duration
at which age the chickens may be vaccinated with an appropriate
inactivated IBV
vaccine.
4.3
CONTRAINDICATIONS
Do not use in sick animals.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Maternally derived antibody (MDA) can interfere with the development
of active
immunity. Where it is likely that recent field infection or
vaccination of the parent flock
has stimulated a high antibody titre and consequently a high level of
MDA, the timing
of the vaccination programme should be planned accordingly.
Page 1 of 5
Issued: July 2013
AN. 01269/2012
In any animal population there will be a small number of individuals
which fail to
respond fully to vaccination. Successful vaccination depends upon
correct storage
and administration of the vaccine and the animal’s ability to
respond. Immune
competence can be influenced by genetic factors, intercurrent
infection, age,
nutritional status, concurrent drug therapy, stress, etc.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Care should be taken in the planning and implementation of vaccination
programmes
as vaccin